CUE VS AADI Stock Comparison
Performance
CUE10/100
10/100
CUE returned -33.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
AADI10/100
10/100
AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
CUE75/100
75/100
1 analysts offer 12-month price targets for CUE. Together, they have an average target of 7, the most optimistic target put CUE at 7 within 12-months and the most pessimistic has CUE at 7.
AADI
"Analyst Price Targets" not found for AADI
Sentiment
CUE74/100
74/100
CUE had a bullish sentiment score of 74.32% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 1.65 comments, and 3.88 likes per day.
AADI
"Sentiment" not found for AADI
Technicals
CUE64/100
64/100
CUE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
AADI57/100
57/100
AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.
Earnings
CUE10/100
10/100
CUE has missed earnings 6 times in the last 20 quarters.
AADI10/100
10/100
AADI has missed earnings 9 times in the last 20 quarters.
Profit
CUE10/100
10/100
Out of the last 20 quarters, CUE has had 0 profitable quarters and has increased their profits year over year on 0 of them.
AADI13/100
13/100
Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
CUE40/100
40/100
CUE has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
AADI39/100
39/100
AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Cue Biopharma, Inc. Summary
Nasdaq / CUE
Healthcare
Biotechnology
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Aadi Bioscience, Inc. Common Stock Summary
Nasdaq / AADI
Healthcare
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare CUE to other companies in the same or a similar industry.